Creative Medical Technology Holdings Inc (CELZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Creative Medical Technology Holdings Inc (CELZ) has a cash flow conversion efficiency ratio of -0.216x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.32 Million) by net assets ($6.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Creative Medical Technology Holdings Inc to measure how much of total assets are equity-financed.
Creative Medical Technology Holdings Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Creative Medical Technology Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Creative Medical Technology Holdings Inc (CELZ) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Creative Medical Technology Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Creative Medical Technology Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baronsmead Second Venture Trust Plc
LSE:BMD
|
-0.008x |
|
ROUTE1 INC.
F:3R6N
|
-0.683x |
|
Lanesborough Real Estate Investment Trust
V:LRT-UN
|
0.011x |
|
NuGen Medical Devices Inc
V:NGMD
|
0.072x |
|
BLACK PEARL ZY-10
F:7ZX
|
-0.011x |
|
Netcall plc
LSE:NET
|
0.012x |
|
Palatin Technologies Inc
NYSE MKT:PTN
|
0.838x |
|
Quest PharmaTech Inc
V:QPT
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Creative Medical Technology Holdings Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Creative Medical Technology Holdings Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Creative Medical Technology Holdings Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.52 Million | $-5.86 Million | -0.778x | +6.90% |
| 2024-12-31 | $6.34 Million | $-5.30 Million | -0.836x | -7.71% |
| 2023-12-31 | $10.34 Million | $-8.03 Million | -0.776x | -57.92% |
| 2022-12-31 | $15.86 Million | $-7.80 Million | -0.491x | -126.63% |
| 2021-12-31 | $10.22 Million | $-2.22 Million | -0.217x | -2086.29% |
| 2020-12-31 | $-39.80 Million | $-434.56K | 0.011x | -92.74% |
| 2019-12-31 | $-8.07 Million | $-1.21 Million | 0.150x | -42.95% |
| 2018-12-31 | $-3.99 Million | $-1.05 Million | 0.263x | -33.79% |
| 2017-12-31 | $-2.24 Million | $-889.62K | 0.398x | -85.90% |
| 2016-12-31 | $-157.79K | $-445.23K | 2.822x | +3443.05% |
| 2015-12-31 | $-183.80K | $-14.64K | 0.080x | -29.63% |
| 2014-12-31 | $-153.04K | $-17.32K | 0.113x | -38.23% |
| 2013-12-31 | $-125.03K | $-22.91K | 0.183x | +6.76% |
| 2012-12-31 | $-97.75K | $-16.77K | 0.172x | -11.29% |
| 2011-12-31 | $-72.16K | $-13.96K | 0.193x | -31.88% |
| 2010-12-31 | $-48.11K | $-13.66K | 0.284x | -71.50% |
| 2009-12-31 | $-30.85K | $-30.74K | 0.996x | +101.32% |
| 2008-12-31 | $757.00 | $-57.16K | -75.514x | -15375.15% |
| 2007-12-31 | $26.35K | $-12.86K | -0.488x | -995.05% |
| 2006-12-31 | $20.89K | $1.14K | 0.055x | -- |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more